R21/Matrix-M疟疾疫苗的公共卫生影响与成本效果:一项数学建模研究
研究利用布基纳法索2b期试验3年随访数据拟合抗环子孢子蛋白抗体滴度与疫苗效力的半机制模型,并在3期试验中验证,再整合传播模型估计撒哈拉以南非洲15年内的临床病例、疟疾死亡和DALY避免数及成本效果。在PfPR2-10中位数20%(范围3%-65%)下,四剂次R21/Matrix-M可避免大量临床病例,每剂3美元时增量成本效果比具有成本效果。
要点
- 抗环子孢子蛋白抗体滴度满足临床疟疾疫苗效力的保护替代指标标准。
- 常年传播地区每10万名全程接种儿童可避免181 825例临床病例(范围38 815-333 491)。
- 季节性传播地区每10万名全程接种儿童可避免202 017例临床病例(范围29 868-405 702)。
核心结论
- 引入R21/Matrix-M疟疾疫苗可能在撒哈拉以南非洲产生实质性的公共卫生获益。
研究设计与样本
- 数学建模研究:利用布基纳法索Nanoro 2b期试验3年随访数据拟合半机制模型,并在3期试验中验证,再整合传播模型估计15年时间范围内的公共卫生影响与成本效果。
- 分析覆盖撒哈拉以南非洲多种传播强度地区,报告PfPR2-10中位数20%(范围3%-65%)的估计值。
主要发现
- 抗环子孢子蛋白抗体滴度满足作为临床疟疾疫苗效力保护替代指标的标准。
- 按年龄实施四剂次方案,常年传播地区每10万名全程接种儿童可避免181 825例临床病例(范围38 815-333 491)。
- 季节性传播地区每10万名全程接种儿童可避免202 017例临床病例(范围29 868-405 702);季节性接种或混合接种方案获得相似估计。
- 假设疫苗每剂3美元,常年传播地区每避免1例临床病例的增量成本为7美元(范围4-48),季节性传播地区为6美元(范围3-63)。
- 常年传播地区每避免1个DALY的增量成本为34美元(范围29-139),季节性传播地区为30美元(范围22-172);PfPR2-10较高地区的成本效果比更低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The R21/Matrix-M vaccine has demonstrated high efficacy against Plasmodium falciparum clinical malaria in children in sub-Saharan Africa. Using trial data, we aimed to estimate the public health impact and cost-effectiveness of vaccine introduction across sub-Saharan Africa. METHODS: We fitted a semi-mechanistic model of the relationship between anti-circumsporozoite protein antibody titres and vaccine efficacy to data from 3 years of follow-up in the phase 2b trial of R21/Matrix-M in Nanoro, Burkina Faso. We validated the model by comparing predicted vaccine efficacy to that observed over 12-18 months in the phase 3 trial. Integrating this framework within a mathematical transmission model, we estimated the cases, malaria deaths, and disability-adjusted life-years (DALYs) averted and cost-effectiveness over a 15-year time horizon across a range of transmission settings in sub-Saharan Africa. Cost-effectiveness was estimated incorporating the cost of vaccine introduction (dose, consumables, and delivery) relative to existing interventions at baseline. We report estimates at a median of 20% parasite prevalence in children aged 2-10 years (PfPR2-10) and ranges from 3% to 65% PfPR2-10. FINDINGS: Anti-circumsporozoite protein antibody titres were found to satisfy the criteria for a surrogate of protection for vaccine efficacy against clinical malaria. Age-based implementation of a four-dose regimen of R21/Matrix-M vaccine was estimated to avert 181 825 (range 38 815-333 491) clinical cases per 100 000 fully vaccinated children in perennial settings and 202 017 (29 868-405 702) clinical cases per 100 000 fully vaccinated children in seasonal settings. Similar estimates were obtained for seasonal or hybrid implementation. Under an assumed vaccine dose price of US$3, the incremental cost per clinical case averted was $7 (range 4-48) in perennial settings and $6 (3-63) in seasonal settings and the incremental cost per DALY averted was $34 (29-139) in perennial settings and $30 (22-172) in seasonal settings, with lower cost-effectiveness ratios in settings with higher PfPR2-10. INTERPRETATION: Introduction of the R21/Matrix-M malaria vaccine could have a substantial public health benefit across sub-Saharan Africa. FUNDING: The Wellcome Trust, the Bill & Melinda Gates Foundation, the UK Medical Research Council, the European and Developing Countries Clinical Trials Partnership 2 and 3, the NIHR Oxford Biomedical Research Centre, and the Serum Institute of India, Open Philanthropy.
引用
- Schmit N, Topazian HM, Natama HM, et al. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. Lancet Infect Dis. 2024. PMID: 38342107. doi:10.1016/S1473-3099(23)00816-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。